Escient Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Neurocrine Biosciences, Inc.

Chemregen, Inc.

Sanford-burnham Medical Research Institute

Human Biomolecular Research Institute

Smithkline Beecham (cork) Ltd

Sb Cork

Smithkline Beecham Corporation

Almirall, S.a.

Marion Lanier

Esther Martinborough

Marcus F Boehm

Liming Huang

Adam Richard Yeager

Marcos Sainz

Brandon Selfridge

Jason W Brown

Benjamin Jones

Xiaolun Wang

Andre A Kiryanov

Joanne Miura

Anthony Ivetac

Sean Timothy Murphy

Jon Kuehler

Melinda Davis

John R Cashman

Mark Mercola

John Patrick Williams

Dennis Schade

John Edward Tellew

Erik Willems

James R McCarthy

Mustapha Haddach

Manisha Moorjani

Charles Q Huang

Zhiyong Luo

Yongsheng Chen

Deborah Slee

John P Williams

Sean Murphy

Emily Lin

Xiaohu Zhang

Binh G Vong

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 dependent condition more specifically, by contacting the MRGPR X2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of mas-related g-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein A, B, C, D, E, G, W, Y, Z, R, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of mas-related G-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of Mas-related G-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPRX2 or a MRGPRX2 ortholog generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein D, W, Z, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.

6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD

The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.

Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R, R, R, R, R, R, R, R, R, Rare as described herein.

Compounds for stem cell differentiation

The present invention provides compounds of the formula:  which are useful as inhibitors of PHD and pharmaceutical compositions thereof.

Growing community of inventors

San Diego, CA, United States of America

Marion Lanier